ËýÀ¿ÕÉÔÁ´¡Ê¤Þ¤ó¤»¤¤¤¸¤ó¤Õ¤¼¤ó¡Ëchronic renal failure¡¡chronic kidney failure |
|---|
|
¢£¸¶°ø¡§
¿ÕÉÔÁ´¤ÎÊݸ´ü¤«¤éËö´ü¿ÕÉÔÁ´¤Ë¿Ê¤ß¡¢Æ©ÀÏÎÅË¡¤ò³«»Ï¤¹¤ë´µ¼Ô¿ô¤Ïǯ´Ö3Ëü¿Í¤ò±Û¤¨¤ë¾õ¶·¤È¤Ê¤Ã¤Æ¤¤¤Þ¤¹¡£ ¤Þ¤¿¡¢¤É¤ó¤Ê¸¶°ø¤Ç¤¢¤Ã¤Æ¤âËýÀŪ¤Ë¿Õµ¡Ç½¤Ë¾ã³²¤¬À¸¤¸¤¿ÉÂÂÖ¤òËýÀ¿Õ¼À´µchronic kidney disease;CKD¤È¸Æ¤ó¤Ç¤¤¤Þ¤¹¡£¡Êkidney disease outcome quality initiative;K/DOQI¤ÎÆ©Àϳ«»ÏÁ°¤Î¿ÕÉÔÁ´´µ¼Ô¤Î¼£ÎÅ¥¬¥¤¥É¥é¥¤¥ó¤Ë¤è¤ë¡Ë
¢£¼£ÎÅ¡§ ¸¶°ø¼À´µ¤Î¼£ÎŤ¬É¬Íפǡ¢¼ÂÎã¤È¤·¤Æ¤Ï·ìÅüÃÍ¡¢·ì°µ¡¢Ç¢ÃÁÇò¤Î¥³¥ó¥È¥í¡¼¥ë¤Ê¤É¤¬¹Ô¤ï¤ì¤Þ¤¹¡£ ¤Þ¤¿À¸³è»ØÆ³¤ä¿©»öÎÅË¡¤âɬÍפǡ¢¸Ä¡¹¤Î´µ¼Ô¤ÎÀ¸³è´Ä¶¤Ê¤É¤ËŬ¹ç¤µ¤»¤¿»ØÆ³¤ò¼õ¤±¤ë¤³¤È¤¬½ÐÍè¤Þ¤¹¡£ ¹â·ì°µ¤Ç·ì°µÄã²¼¤òÂ¥¿Ê¤µ¤»¤ë¾ì¹ç¡¢¿Õµ¡Ç½¤Î°ÂÄê¤ò¿Þ¤ëÌÜŪ¤Ç·îÆü¤ò¤«¤±¤ÆÄ´À°¤¹¤ë¤è¤¦¤Ë¤·¤Þ¤¹¡£ Æ©ÀÏÎÅË¡¤Ë°Ü¤é¤¶¤ë¤ò¤¨¤Ê¤¤¾ì¹ç¡¢´µ¼Ô¤È²È²¤Ë¤½¤Î¼£ÎŤ˴ؤ¹¤ëÀµ¤·¤¤Ç§¼±¤ÈÃ챤ò¡¢Á°¤â¤Ã¤Æ¿È¤ËÃ失¤Æ¤ª¤¯¤³¤È¤¬Ë¾¤Þ¤·¤¤¤Ç¤¹¡£
¢£½èÊýÎã¡§ ¹â·ì°µ¡§¹ß°µÌô¡§¥¢¥ó¥¸¥ª¥Æ¥ó¥·¥ó¶¼õÍÆÂÎÙɹ³Ìô¡¦¥Ð¥ë¥µ¥ë¥¿¥óvalsartan¡£¾¦ÉÊ̾¡§¥Ç¥£¥ª¥Ñ¥ó[¥Á¥Ð¥¬¥¤¥®¡¼-¥Î¥Ð¥ë¥Æ¥£¥¹]¡Ê20mg)£±Æü£±²ó20¡Á80mg¡£¡ÊÉûºîÍÑ¡§·ì´ÉÉâ¼ð¡¢´Î±ê¡¢¥·¥ç¥Ã¥¯¡¢°Õ¼±¾Ã¼º¤½¤Î¾¡Ë ¹âÃâÁÇ·ì¾É¡§ÃæÆÇ¼£ÎÅÌô¡Ê²òÆÇ¡Ë¡§µå·ÁµÛÃåúspherical cabonaceouse adsorbent¡£¾¦ÉÊ̾¡§¥¯¥ì¥á¥¸¥óºÙγ¡Ê2g/Êñ¡Ë[¸â±©-»°¶¦]1Æü3²ó6g¡£ ¡Ê¾ºÞ¤òµÛÃ塦ÇÓÝõ¤µ¤»¤ë¤¿¤á¡¢Ã±ÆÈ»ÈÍѤΤ³¤È¡£¤½¤Î¤¿¤á¿¾¯ÆâÉþ»þ´Ö¤¬¤º¤ì¤Æ¤âí´í°¤»¤ºÉþÍѤ¹¤Ù¤¡£Ëɼ¾Êݸ¡£ÉûºîÍÑ¡§Ê¢ÉôËÄËþ´¶¡¢¿©ÍßÉÔ¿¶¡¢ÊØÈ뤽¤Î¾¡Ë ÉϷ졧¤·ìÌô-¥¨¥ê¥¹¥í¥Ý¥¨¥Á¥óÀ½ºÞ¡¦¥¨¥Ý¥¨¥Á¥ó¥¢¥ë¥Õ¥¡¡Ê°äÅÁ»ÒÁȤߴ¹¤¨¡Ë epoetin alfa(genetcal recombination)¡£ ¾¦ÉÊ̾¡§¥¨¥¹¥Ý¡¼Èé²¼Ãí1²ó6000¡Á1,2000IU¡£2½µ¤Ë1,2²óÈé²¼Ãí¼Í¡£[¥¥ê¥ó¥Ó¡¼¥ë](ÉûºîÍÑ¡§ ¥·¥ç¥Ã¥¯¡¢¥¢¥Ê¥Õ¥£¥é¥¥·¡¼Í;ɡ¢Ç¾¹¼ºÉ¡¢¿´¶Ú¹¼ºÉ¡¢´Îµ¡Ç½¾ã³²¤½¤Î¾¡Ë Éâ¼ð¡§¥ë¡¼¥×ÍøÇ¢Ìô-¥Õ¥í¥»¥ß¥Éfurosemide¡£¥é¥·¥Ã¥¯¥¹(20,40mg)1Æü1²ó40¡Á80mg¡£ ¡ÊÍøÇ¢¸ú²Ì¤¬¶¯¤¯¡¢Ã¦¿å¡¢ÅŲò¼Á°Û¾ï¡¢·ìÀòºÉÀò¾É¤Ê¤É¤òͶ°ú¤µ¤»¤ë´í¸±À¤¬¤¢¤ë¤¿¤áÍÑÎ̤ËÃí°Õ¡£ÉûºîÍÑ¡§¥·¥ç¥Ã¥¯¡¢¥¢¥Ê¥Õ¥£¥é¥¥·¡¼Í;ɡ¢ºÆÀ¸ÉÔÎÉÀÉÏ·ì¡¢¿åË¢ÀÎàÅ·á×áì¡¢Æñİ¡¢´Ö¼ÁÀÇٱꤽ¤Î¾¡Ë |